<DOC>
	<DOCNO>NCT02923609</DOCNO>
	<brief_summary>The primary objective study investigate safety efficacy transendocardial CD34+ cell therapy patient HFpEF evaluate change myocardial structure function , myocardial perfusion electrical activity , biomarkers neurohormonal activation , patient exercise capacity clinical outcome . The secondary objective study well define patophysiological background HFpEF use multimodality image platform , include data electro-anatomical mapping , cardiac MRI , 2D 3D echocardiography , high resolution electrocardiography , cardiac catheterization</brief_summary>
	<brief_title>Cell Therapy HFpEF</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Preserved leave ventricular systolic function echocardiography ( LVEF &gt; 50 % ) Evidence diastolic dysfunction echocardiography ( E/e ' &gt; 15 ) Symptoms heart failure ( NYHA functional class II III ) NTproBNP level &gt; 300 pg/ml Acute multiorgan failure History malignant disease within 5 year Diminished functional capacity due noncardiac comorbidities ( COPD , PAOD , morbid obesity ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>